Pappas, Chiesi Venture Fund Joins Ranks of Pharma & VC Partnerships
Art Pappas has overseen his own firm’s venture capital investments for 20 years. Now the veteran life sciences investor is adding on a new role, scoping out investment opportunities for a pharmaceutical company’s new venture fund.
Italian pharma Chiesi Group’s recently-launched Chiesi Ventures will focus on investing in companies developing treatments for rare and orphan diseases. The bulk of the money for investments will come from Chiesi, but the fund will be managed by Durham, NC-based A.M. Pappas & Associates, whose own investing unit, Pappas Ventures, has backed numerous companies that have found exits via acquisition or initial public offering.